Balyasny Asset Management’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $273M | Buy |
555,473
+546,969
| +6,432% | +$297M | 0.35% | 39 |
|
|
2025
Q4 | $4.93M | Buy |
+8,504
| New | +$4.81M | 0.01% | 1403 |
|
|
2025
Q3 | – | Sell |
-244,113
| Closed | -$114M | – | 3475 |
|
|
2025
Q2 | $99M | Buy |
244,113
+211,079
| +639% | +$88.3M | 0.15% | 154 |
|
|
2025
Q1 | $16.4M | Buy |
33,034
+22,676
| +219% | +$12.3M | 0.03% | 680 |
|
|
2024
Q4 | $5.39M | Sell |
10,358
-15,605
| -60% | -$8.58M | 0.01% | 1247 |
|
|
2024
Q3 | $16.1M | Sell |
25,963
-103,807
| -80% | -$61.4M | 0.03% | 732 |
|
|
2024
Q2 | $71.8M | Buy |
129,770
+95,433
| +278% | +$54.7M | 0.13% | 198 |
|
|
2024
Q1 | $20M | Sell |
34,337
-218,646
| -86% | -$123M | 0.03% | 615 |
|
|
2023
Q4 | $134M | Buy |
252,983
+114,434
| +83% | +$55.4M | 0.25% | 70 |
|
|
2023
Q3 | $70.1M | Buy |
138,549
+133,721
| +2,770% | +$71.3M | 0.14% | 188 |
|
|
2023
Q2 | $2.52M | Sell |
4,828
-799
| -14% | -$431K | 0.01% | 1304 |
|
|
2023
Q1 | $3.24M | Sell |
5,627
-36,367
| -87% | -$20.5M | 0.01% | 1245 |
|
|
2022
Q4 | $23.1M | Buy |
41,994
+33,399
| +389% | +$17.7M | 0.06% | 430 |
|
|
2022
Q3 | $4.36M | Sell |
8,595
-92,584
| -92% | -$51.8M | 0.01% | 1072 |
|
|
2022
Q2 | $55M | Buy |
+101,179
| New | +$55.7M | 0.18% | 132 |
|
|
2022
Q1 | – | Sell |
-123,297
| Closed | -$70.8M | – | 2849 |
|
|
2021
Q4 | $82.3M | Buy |
123,297
+12,855
| +12% | +$8.03M | 0.28% | 58 |
|
|
2021
Q3 | $63.1M | Sell |
110,442
-41,284
| -27% | -$22.7M | 0.26% | 72 |
|
|
2021
Q2 | $76.5M | Buy |
151,726
+110,449
| +268% | +$52.1M | 0.36% | 45 |
|
|
2021
Q1 | $18.8M | Buy |
+41,277
| New | +$19.7M | 0.09% | 296 |
|
|
2020
Q3 | – | Sell |
-83,732
| Closed | -$34.6M | – | 1601 |
|
|
2020
Q2 | $30.3M | Buy |
+83,732
| New | +$28.1M | 0.26% | 95 |
|
|
2019
Q3 | – | Sell |
-18,877
| Closed | -$5.54M | – | 1588 |
|
|
2019
Q2 | $5.54M | Buy |
18,877
+9,639
| +104% | +$2.65M | 0.04% | 576 |
|
|
2019
Q1 | $2.53M | Sell |
9,238
-232
| -2% | -$57.7K | 0.02% | 759 |
|
|
2018
Q4 | $2.12M | Buy |
9,470
+4,525
| +92% | +$1.06M | 0.02% | 706 |
|
|
2018
Q3 | $1.21M | Sell |
4,945
-13,126
| -73% | -$3.02M | 0.01% | 1129 |
|
|
2018
Q2 | $3.74M | Sell |
18,071
-60,370
| -77% | -$12.8M | 0.02% | 742 |
|
|
2018
Q1 | $16.2M | Buy |
78,441
+77,241
| +6,437% | +$16.2M | 0.07% | 384 |
|
|
2017
Q4 | $228K | Sell |
1,200
-168,114
| -99% | -$32.2M | ﹤0.01% | 1846 |
|
|
2017
Q3 | $32M | Buy |
169,314
+101,028
| +148% | +$18.3M | 0.13% | 222 |
|
|
2017
Q2 | $11.9M | Buy |
68,286
+58,105
| +571% | +$9.76M | 0.05% | 486 |
|
|
2017
Q1 | $1.56M | Sell |
10,181
-152,193
| -94% | -$23.3M | 0.01% | 977 |
|
|
2016
Q4 | $22.9M | Buy |
+162,374
| New | +$23.9M | 0.12% | 235 |
|
|
2016
Q2 | – | Sell |
-128,985
| Closed | -$19M | – | 1451 |
|
|
2016
Q1 | $18.3M | Buy |
128,985
+27,212
| +27% | +$3.65M | 0.11% | 265 |
|
|
2015
Q4 | $14.4M | Sell |
101,773
-118,170
| -54% | -$15.8M | 0.1% | 270 |
|
|
2015
Q3 | $26.9M | Buy |
219,943
+218,163
| +12,256% | +$28.4M | 0.2% | 135 |
|
|
2015
Q2 | $231K | Sell |
1,780
-196,345
| -99% | -$25.6M | ﹤0.01% | 995 |
|
|
2015
Q1 | $26.6M | Buy |
+198,125
| New | +$25.5M | 0.22% | 145 |
|
|
2013
Q3 | – | Sell |
-48,713
| Closed | -$4.12M | – | 711 |
|
|
2013
Q2 | $4.12M | Buy |
+48,713
| New | +$4.06M | 0.07% | 335 |
|
Other funds holding TMO
VCM
Balyasny Asset Management's TMO Position: Q1 2026 in Review
Balyasny Asset Management increased its Thermo Fisher Scientific (TMO) stake by 6,432% in Q1 2026, buying an estimated $297M and bringing the position to 555,473 shares worth $273M. The position accounts for 0.35% of the portfolio, ranked #39.
Balyasny Asset Management first reported a position in TMO in Q2 2013 and has held it in 37 quarters since. 2,587 funds tracked by Wall St. Rank hold TMO as of Q1 2026.
- Balyasny Asset Management held 555,473 shares of Thermo Fisher Scientific worth $273M as of Q1 2026.
- Balyasny Asset Management bought 546,969 Thermo Fisher Scientific shares in Q1 2026, an estimated $297M.
- Thermo Fisher Scientific made up 0.35% of Balyasny Asset Management's portfolio in Q1 2026, its #39 holding.
- Balyasny Asset Management first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 37 quarters since.
- 2,587 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.
Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.